sclerosis causes the immune system to attack the insulating tissue around nerve fibers. Copaxone is an injection designed to work with the bodys immune system to cut relapses of the disease.
Natco Pharma CEO Rajeev Nannapaneni had earlier said that sales would jump 62% in two years once it started selling a generic version of Copaxone.
On Thursday, shares of Natco touched a 52-week high at R826 on the BSE after prospects for its generic version of Copaxone got a boost from the favourable US court ruling. The shares closed 4.02% up at R792.45.
Meanwhile, Natco reported a consolidated revenue of R188 crore with a net profit of R27 crore, against R21 crore on a revenue base of R191 crore last year. The Ebitda margins have expanded to 31% of the revenues, from 26% last year.